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Abstract
In an ongoing clinical phase I/II study, 16 pediatric patients suffering from high risk leukemia/tumors received highly
purified donor natural killer (NK) cell immunotherapy (NK-DLI) at day (+3) +40 and +100 post haploidentical stem cell
transplantation. However, literature about the influence of NK-DLI on recipient’s immune system is scarce. Here we present
concomitant results of a noninvasive in vivo monitoring approach of recipient’s peripheral blood (PB) cells after transfer of
either unstimulated (NK-DLI(unstim)) or IL-2 (1000 U/ml, 9–14 days) activated NK cells (NK-DLI(IL-2 stim)) along with their ex vivo
secreted cytokine/chemokines. We performed phenotypical and functional characterizations of the NK-DLIs, detailed flow
cytometric analyses of various PB cells and comprehensive cytokine/chemokine arrays before and after NK-DLI. Patients of
both groups were comparable with regard to remission status, immune reconstitution, donor chimerism, KIR mismatching,
stem cell and NK-DLI dose. Only after NK-DLI(IL-2 stim) was a rapid, almost complete loss of CD56
(bright)CD16
(dim/2) immune
regulatory and CD56
(dim)CD16
(+) cytotoxic NK cells, monocytes, dendritic cells and eosinophils from PB circulation seen
10 min after infusion, while neutrophils significantly increased. The reduction of NK cells was due to both, a decrease in
patients’ own CD69
(2) NCR
(low)CD62L
(+) NK cells as well as to a diminishing of the transferred cells from the NK-DLI(IL-2 stim)
with the CD56
(bright)CD16
(+/2)CD69
(+)NCR
(high)CD62L
(2) phenotype. All cell counts recovered within the next 24 h. Transfer
of NK-DLI(IL-2 stim) translated into significantly increased levels of various cytokines/chemokines (i.e. IFN-c, IL-6, MIP-1b)i n
patients’ PB. Those remained stable for at least 1 h, presumably leading to endothelial activation, leukocyte adhesion and/or
extravasation. In contrast, NK-DLI(unstim) did not cause any of the observed effects. In conclusion, we assume that the
adoptive transfer of NK-DLI(IL-2 stim) under the influence of ex vivo and in vivo secreted cytokines/chemokines may promote
NK cell trafficking and therefore might enhance efficacy of immunotherapy.
Citation: Brehm C, Huenecke S, Quaiser A, Esser R, Bremm M, et al. (2011) IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of
Peripheral Blood Cells: Concomitant Results to a Phase I/II Study. PLoS ONE 6(11): e27351. doi:10.1371/journal.pone.0027351
Editor: Francesco Dieli, University of Palermo, Italy
Received June 3, 2011; Accepted October 14, 2011; Published November 9, 2011
Copyright:  2011 Brehm et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was supported by the ‘‘Deutsche Forschungsgemeinschaft (DFG)’’ (GRK 1172), ‘‘Frankfurter Stiftung fu ¨r krebskranke Kinder’’ and ‘‘Hilfe fu ¨r
krebskranke Kinder Frankfurt e.V.’’, the ‘‘A. Gutermuth Stiftung’’, as well as the ‘‘LOEWE Center for Cell and Gene Therapy Frankfurt’’ funded by: Hessisches
Ministerium fu ¨r Wissenschaft und Kunst (HMWK); funding reference number: III L 4- 518/17.004 (2010). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Claudia.Brehm@kgu.de
Introduction
Advanced cell therapy trials with donor natural killer (NK) cells
post haploidentical stem cell transplantation (haplo-SCT) provide
a promising treatment option for patients with high risk leukemia
and tumors. While the established T cell therapies are associated
with the risk of graft-versus-host disease (GvHD), NK cells may
mediate graft-versus-leukemia/tumor (GvL/T) effects without
induction of GvHD. Therefore, immunotherapy with highly
purified NK cell donor lymphocyte infusions (NK-DLI) in
recipients of haplo-SCT could serve as an attractive alternative
cell therapy [1–3].
NK cells are key players of the innate immune system, able to
distinguish between healthy and malignant cells. NK cell
cytotoxicity is mediated by a balance of activating and inhibitory
signals [4]. Activating receptors like the natural cytotoxicity
receptors (NCR) NKp30, NKp44, and NKp46 and the NK group
2D (NKG2D) receptor trigger cytotoxicity against malignant cells
[5]. In contrast, the predominance of inhibitory signals is mediated
by killer immunoglobulin-like receptors (KIR) [6–8]. Human
CD56
+CD3
2 NK cells in the peripheral blood (PB) can be
subdivided into a major CD56
dimCD16
+ population which
is highly cytotoxic and a smaller immune regulatory
CD56
brightCD16
dim/2 population with a potent cytokine produc-
ing capacity [9]. In the early phase of reconstitution post SCT, an
unusually high percentage of CD56
brightCD16
dim/2 NK cells can
be determined, which gradually declines in the post-transplant
period [10]. A part of these emerging cells are immature with
impaired cytotoxic function [11], which makes adoptive donor
NK cell immunotherapy post SCT needful to enhance GvL/T
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27351effects. To date, first trials and ongoing clinical phase I/II studies
show the feasibility of using freshly purified or interleukin-2 (IL-2)
activated NK-DLIs for the treatment of high risk patients suffering
from leukemia or tumors in both, non-transplant settings and after
haplo-SCT as an additional immunotherapy [1–3,12–16]. These
first immunotherapy trials show that NK-DLIs are infused without
immediate adverse events. Moreover, a clinical benefit was
reported by Rubnitz et al. showing a 2-year event-free survival of
100% for ten children with favorable- and intermediate-risk acute
myeloid leukemia (AML) in first complete remission post
haploidentical NK cell immunotherapy [3].
However, to date there is a lack of literature concerning studies
investigating the influence of allogeneic NK-DLIs on the immune
system of the host. Here, we present concomitant data about the
noninvasive approach of an in vivo monitoring of recipient’s cells of
the innate and adaptive immune system following treatment with
unstimulated in comparison to IL-2 activated NK cells post haplo-
SCT. Quantification of various leukocyte subsets together with
analysis of cytokine/chemokine plasma levels before and after
NK-DLI applications revealed novel information on the immune
status of patients undergoing adaptive NK cell therapies.
Materials and Methods
Ethics Statement
The study was approved by the Medical Ethics Committee of
the Frankfurt University Hospital in 2003 (Ref. number 262/03).
Written informed consent was obtained from all children and
parents/legal guardians of the children.
Study design of phase I/II NK cell immunotherapy
Between 2003 and 2011, 16 pediatric patients suffering from
high risk leukemia or tumors underwent haplo-SCT and
additionally received NK cells from their respective donor (Clin
Gov No. NCT 01386619, Table 1+2). For haplo-SCT, peripheral
blood stem cells (PBSC) were purified immunomagnetically either
by CD34-selection or CD3/CD19-depletion (Clin Gov No. NCT
00945126) as described previously [16,17]. After haplo-SCT,
highly purified donor NK cells were transfused around (+d 3), +d
40 and +d 100 as we described earlier (Fig. S1A+B) [1,12,18]. So
far, nine patients received highly purified, freshly isolated
unstimulated NK cells (NK-DLIunstim, group I) and nine patients
were treated with further ex vivo IL-2 activated NK cells along with
their corresponding ex vivo secreted cytokines/chemokines (NK-
DLIIL-2 stim, group II). In two patients both, NK-DLIunstim and
NK-DLIIL-2 stim were administered (No. 8 and 9). In summary, 29
NK-DLIs were transfused (n=15 NK-DLIIL-2 stim and n=14 NK-
DLIunstim); of those 14 freshly and 15 following cryopreservation
(Table 2 and Fig. S1A+B). According to the study protocol,
cryopreservation was an option to verify two to three NK cell
applications and reduce the physical loading of repeating
leukapheresis for the donors. Targeted cell doses were $1610
7/
kg BW CD56
+CD3
2 NK cells, with ,1610
5/kg BW contami-
nating CD3
+ T cells. Defined study exclusion criteria prior to NK-
DLI were graft failure or patients with persisting acute or chronic
GvHD. Study discontinuation criteria were severe GvHD ($grade
III) or other toxicities.
Purification of CD56
+CD3
2 NK cells, ex vivo activation
and quality control
NK cells were collected from two unstimulated leukapheresis
products, without G-CSF stimulation, from healthy haploidentical
donors. The two-step purification procedure (CliniMACSs cell
selection system; Miltenyi Biotec, Bergisch Gladbach, Germany)
included first a CD3
+ T cell depletion step with an ensuing CD56
+
NK cell selection from the CD3
2 fraction, obeying good
manufacturing practice (GMP) as we described previously
[1,18]. In case of group I patients receiving NK-DLIunstim, the
leukapheresis was performed at day 210 prior and +40 post SCT
(Fig. S1A). At day +40, NK-DLIunstim was split while one part was
applied freshly directly at the end of the purification process, and
the other part was cryopreserved for the day +100 application.
The processed NK-DLIunstim from day 210 was also split and
cryopreserved for the NK cell applications on day +3 and +100.
For cryopreservation, NK cell products were concentrated and
resuspended in X-VIVO 10 media diluted 1:2 with 20% dimethyl
sulfoxide (DMSO).
In case of group II patients receiving NK-DLIIL-2 stim, two
leukapheresis products collected on day +29 and +30 post SCT
were pooled for the NK cell purification process (Fig. S1B).
Following the two-step CD3-depletion/CD56-selection purifica-
tion procedure, NK cells were further expanded and activated
using 1000 U/mL rhIL-2 (ProleukinH Novartis Pharma GmbH,
Nu ¨rnberg, Germany) for 10 (9 to 14) days obeying GMP. NK cells
were cultured in X-VIVO 10 media in VueLife
TM cell culture
bags (CellGenix Technology, Freiburg, Germany), supplemented
with 5% heat-inactivated human fresh frozen plasma (Red Cross
Blood Donor Service, Baden-Wu ¨rttemberg-Hessen, Frankfurt,
Germany) at 37uC and 5% CO2. Fresh media and IL-2 were
added every three days. Following the ex vivo stimulation, the NK
cell product was split up, while one half was infused freshly at day
+40 and the other was cryopreserved and applied at day +100 post
SCT (Fig. S1B).
For quality control, analyses of purity of NK cells, residual T
cells, cell viability, NK cell receptor repertoire (NCRs, NKG2D)
and cytotoxic activity against K562 cells were performed [16,19].
Sample collection and preparation
Immune reconstitution of various leukocyte subsets in the PB of
all patients was monitored regularly; within the first three months
post SCT weekly, from month four to six twice a month, followed
by a period of monthly analyses. For our concomitant in vivo
monitoring during NK-DLI, PB samples were collected before
(pre), 10 min, 1 h, 4 h and 24 h after the end of NK cell infusion
(Fig. S1C). Flow cytometric analyses were performed within 4 h.
For cytokine/chemokine analyses, plasma of PB samples collected
during in vivo monitoring and supernatants of NK-DLIIL-2 stim
collected immediately prior to infusion, were stored at 280uC
until analysis.
Flow cytometric analysis for quantification of leukocyte
subsets and cytotoxicity assay
Flow cytometric analyses were performed to determine (i)
quality control of the administered NK-DLI, (ii) the specific
influence of NK-DLI on the patient’s immune system and (iii) the
overall cellular immune reconstitution post SCT in all 16 patients.
Monoclonal antibodies (mAB) conjugated with fluorescein-isothio-
cyanate (FITC), phycoerythrin (PE), phycoerythrin-Texas RedH
tandem (ECD), phycoerythrin-cyanine-5 (PC-5) and phycoery-
thrin-cyanine-7 (PC-7) were used against following antigens
(clones): CD3 (UCHT1) and (SK7)
#, CD4 (13B8.2), CD4
(SFCI12T4D11), CD8 (SFCI21Thy2D3(T8)), CD14 (RMO52)
2,
CD14+CD16 (RMO522+3G8), CD16 (3G8), CD19 (J3-119),
CD33 (D3HL60.251), CD45 (B3821F4A)
1, CD45 (J.33), CD56
(N901) and (NCAM16.2)
1#, CD62L (DREG56), CD69
(TP1.55.3)
1, CD85k/ILT-3 (ZM3.8), CD123 (107D2), CD336/
NKp44 (Z231), (
1IgG2b,
2IgG2a, all other IgG1 isotypes) (
#BD
Biosciences, Heidelberg, Germany, all other Beckman Coulter,
Influence of NK-DLI(IL-2 Stim) on PB Cells
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mycin D (7-AAD) was used. An automated lyse/no-wash
procedure was used with a fixation step on a TQ-Prep
TM
Workstation (Beckman Coulter, Krefeld, Germany). Absolute
lymphocyte subset counts were calculated via leukocyte counts
measured by CoulterH Ac.T diff
TMCounter (Beckman Coulter,
Krefeld, Germany). Measurements of myeloid DC, plasmacytoid
DC and NK cells were carried out in a single-platform approach
Table 2. NK cell applications phase I/II study: NK-DLI post haplo-SCT.
No.
Day of
NK-DLI
post SCT
fresh (f)
cryo (c) Volume
CD56
+
CD3
2
CD56
+
CD3
+
CD56
2
CD3
+
total
CD3
+
1. KIR MM
(GvL/T)
2. KIR MM
(GvL/T)
1. KIR MM
(HvG)
2. KIR MM
(HvG)
[ml] [10
6/BW] [10
3/BW] [10
3/BW] [10
3/BW] (excluding A3/A11 mismatch)
Group I: Patients receiving NK-DLIunstim
1 +2 c 261 24.7 n.s. n.s. 53.4 2DL1/C2 3DL1/Bw4 2DL1/C2 –
2 +3 c 499 13.5 n.s. n.s. 4.5 2DL1/C2 – 3DL1/Bw4 –
3 +2 c 168 32.3 n.s. n.s. 1.8 2DL1/C2 – 2DL1/C2 –
+54 f 77 15.5 n.s. n.s. 8.2
4 +2 c 154 6.6 n.s. n.s. 0.8 – – 2DL1/C2 –
+49 f 143 12.7 n.s. n.s. 8.1
+103 c 75 3.2 n.s. n.s. 0.4
5 +3 c 198 9.9 n.s. n.s. 0.6 2DL1/C2 – – –
+42 f 115 7.7 n.s. n.s. 4.1
6 +2 c 152 6.9 n.s. n.s. 4.8 – – 2DL2/C1 –
7 +42 f 92 38.3 n.s. n.s. 2.3 – – 2DL2/3/C1 –
+92 c 60 12.5 n.s. n.s. 0.8
8* +50 f 129 8.7 15.8 ,0.6
# 15.8 3DL1/Bw4 – – –
9* +47 f 210 30.0 37.6 10.4 48.0 2DL3/C1 3DL1/Bw4 – –
Median (total) 14 148 13.1 n.s. n.s. 4.3
11 6/9 6/9
Median (fresh) 6 122 14.1 n.s. n.s. 8.2
1
Mean (fresh) 128 18.8 n.s. n.s. 14.4
Group II: Patients receiving NK-DLIIL-2 stim
8* +70 c 183 20.6 81.0 17.3 98.3 3DL1/Bw4 – – –
+116 c 187 8.4 31.3 12.4 43.7
* +101 f 1155 30.6 18.5 16.1 34.6 2DL3/C1 3DL1/Bw4 – –
10 +40 f 1000 45.1 50.0 7.5 57.5 2DL1/C2 3DL1/Bw4 –
+126 c 376 41.4 43.0 6.9 49.9
11 +35 f 288 7.8 6.0 7.3 13.3 2DL1/C2 – 2DL1/C2 3DL1/Bw4
+109 c 306 13.5 9.6 13.0 22.6
12 +39 f 800 19.1 39.5 8.1 47.6 2DL1/C2 – 2DL1/C2 –
+96 c 148 6.0 22.3 15.3 37.6
13 +41 f 2296 15.0 29.3 2.4 31.7 2DL2/L3/C1 – – –
14 +54 f 319 6.6 8.8 0.3 9.1 – – 2DL2/3/C1 –
+96 c 240 6.1 7.3 8.2 15.5
15 +54 f 684 14.6 11.3 4.1 15.4 2DL1/C2 – 2DL1/C2 –
+98 c 210 7.3 5.7 2.0 7.7
16 +11 f 55 14.9 20.9 31.6 52.5 2DL1/C2 – 2DL1/C2 –
Median (total) 15 306 14.6 18.5 8.1 34.6
11 8/9 6/9
Median (fresh) 8 742 15.0 14.9 7.4 33.2
1
Mean (fresh) 825 19.2 20.2 9.7 32.7
BW: kg/body weight, cryo (c): cryopreserved, fresh (f): freshly applied, f: female, GvL/T: graft-versus-leukemia/tumor, haplo-SCT: haploidentical stem cell transplantation,
HvG: host-versus-graft, KIR: killer cell immunoglobulin-like receptor, m: male, MM: mismatch, No.: number, n.s.: not specified, NK-DLI: NK cell donor lymphocyte infusion,
SCT: stem cell transplantation,
*patients received both NK-DLIunstim and NK-DLIIL-2 stim,
#under detection limit,
1difference statistically not significant,
11difference statistically significant.
doi:10.1371/journal.pone.0027351.t002
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TM fluorospheres (Beckman Coulter, Marseille,
France) [17,20]. On both, CD56
dimCD16
+ and CD56
bright
CD16
dim/2 NK cells, surface expression of NKp44, CD69
activation and the lymph node homing molecule CD62L were
investigated. NK cell cytotoxicity of NK-DLIIL-2 stim and NK-
DLIunstim was tested against the MHC class I negative cell line
K562 at the ratios 1:1 and 10:1 based on a 5-color flow cytometric
single platform assay (Fig. S2A) [19]. Cytotoxicity was defined as
the loss of viable target cells in relation to the mono-cultured
control. All analyses were performed on a 4- or 5-color flow
cytometer, respectively (EPICSH L
TMand FC500, Beckman
Coulter, Krefeld, Germany) and data were further analyzed using
CXP v2.2 software (Beckman Coulter, Krefeld, Germany).
Cytokine and chemokine analysis
Cytokines and chemokines in the plasma of PB samples
obtained during in vivo monitoring and supernatants of the 9–14
days stimulated NK-DLIIL-2 stim were measured using BD
TM
Cytometric Bead Array (CBA) in combination with the BD
FACSArray
TM bioanalyzer (BD Biosciences, Heidelberg, Ger-
many). The human Flex Set was used to detect the secretion of
interleukin (IL) -1b, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12p70,
IL-12/IL-23p40, IL-13, tumor necrosis factor-a (TNF-a), TNF-b,
interferon-c (IFN-c) IFN-c-inducible protein (IP-10), monocyte
chemotactic protein-1 (MCP-1), macrophage inflammatory pro-
tein-a (MIP-1-a), MIP-1b, regulated on activation, normal T cell
expressed and secreted (RANTES), Fas ligand (FasL), granulocyte
colony-stimulating factor (G-CSF), granulocyte macrophage
colony-stimulating factor GM-CSF. In short, 50 ml of the provided
standards or plasma samples were mixed with capture beads
specific for one cytokine and PE detection, and processed
according manufacturer’s instructions. The assay lower detection
limit ranged from 0.2 to 14.7 pg/ml.
KIR and HLA genotyping and chimerism analysis
Typing of KIR genes in PB of both, donors and patients was
performed by PCR-sequence-specific primers and was used to
detect the presence or absence of 19 KIR genes (2DL1-5B, 3DL1-
3, 2DS1-5, 3DS1, 2DP1, 3DP1) as described previously [21]. HLA
were typed using sequence-specific probes and sequence-based
typing (SBT) analysis. KIR/HLA-ligand matching or mismatching
in donor-recipient pairs was evaluated using the KIR receptor –
HLA-ligand mismatch model (‘‘missing KIR ligand model’’). For
quantitation of donor chimerism in the PB and bone marrow
(BM), a semi-quantitative PCR assay based on the amplification of
short tandem repeat (STR) markers was used [22].
Statistical Analyses
Statistical analyses were performed using GraphPad Prism 5.03
(GraphPad Software, San Diego, USA). Biological data were
compared by paired Student t test, Wilcoxon matched-pairs signed
rank test and Mann-Whitney-test depending on paired or
unpaired and Gaussian or non-Gaussian distribution of values.
Differences were considered as significant for p,0.05, p,0.01,
and p,0.001 indicated as *, **, and ***, respectively.
Results
Comparison of NK-DLIunstim and NK-DLIIL-2 stim
In a clinical phase I/II study, 16 pediatric patients received
either freshly isolated, unstimulated NK-DLIs (NK-DLIunstim;
group I) or ex vivo IL-2 stimulated NK-DLIs (NK-DLIIL-2 stim;
group II) from their respective donors, from one up to three times
post haplo-SCT (Table 2). According to the study protocol, the
median application date post SCT was day +2 (range 2–3), +42
(range 11–54) and +101 (range 70–126). After processing, the
median purity of the CD56
+CD3
2 NK cell product was 95%
(range 84.4–98.6). The majority of the concomitant cells were
antigen presenting cells like monocytes and dendritic cells (mDC,
pDC) as we could show previously [23]. The overall median yield
during processing procedure was 54% (range 38.7–84.1). Patients
of both groups received similar NK cell doses in the DLI:
14.6610
6/kg BW (range 6.0–45.1) and 13.1610
6/kg BW (range
3.2–38.3) for NK-DLIIL-2 stim and NK-DLIunstim with no
differences between freshly and cryopreserved DLIs. Concomitant
CD3
+ T cells in the NK-DLI were higher in group II with a
median of 34.6610
3/kg BW (range 7.7–98.3) compared to
4.3610
3/kg BW (range 0.4–53.4) in group I patients. Concerning
fresh NK-DLIs this difference was not statistically significant, thus
a statistical difference was seen in regard to all NK-DLI
applications. Of note, of these overall CD3
+ cells, in group II
approximately two-thirds belonged to the CD56
+CD3
+ NK-like T
cells and one-third to CD56
2CD3
+ T cells, only. Median NK cell
cytotoxicity against MHC class I negative K562 cells in the
effector:target ratios 1:1 and 10:1 was 67% and 88% for NK-
DLIIL-2 stim compared to 30% and 75% for NK-DLIunstim (Fig.
S2A). The improved cytotoxicity of NK-DLIIL-2 stim was related to
a high up-regulation of the activating receptors NKp30, NKp44,
NKp46 and NKG2D. The CD69 activation marker expression
was strongly enhanced as well, whereas the lymph node homing
molecule CD62L was significantly down-regulated upon IL-2
stimulation as we showed previously [16]. Freshly administered
NK-DLIunstim showed a high viability (median 93%) compared to
NK-DLIIL-2 stim which showed a decrease in vital NK cell count to
30–70% during the first three days, followed by a period of
enhanced growth and increasing viability during 9–14 days of IL-2
expansion [16,18].
The applied CD34
+ stem cell dose in the graft was similar in
both groups with a 6.2 times higher CD3
+ T cell count in grafts of
group II compared to group I patients (13.5610
3/kg BW vs.
84.5610
3/kg BW, difference not significant). This was due to a
change in graft purification from CD34-selection to CD3/CD19-
depletion (Table 1). Therefore, patients transplanted with CD3/
CD19 depleted grafts received mycophenolate mofetil (MMF) as
an immunosuppressive therapy to avoid severe GvHD and graft
rejection. Because of a possible negative impact of MMF on NK
cell functionality, the early time point of NK-DLI at day +3 post
SCT has been omitted for these patients. To validate if the
differing graft purifications in group I have any influence of our
presented results, we exemplarily excluded the four patients
receiving CD34 selected grafts from our analyses, whereof only
two fresh NK-DLIunstim were applied (data not shown). Since we
did not see any differences in our results and it confirmed the
overall conclusion, we decided to remain with the total patient
group.
NK-DLI was well tolerated in both groups, besides transient
fever and chills for 24 h in group II patients receiving NK-DLIIL-2
stim. In two patients (No. 9 and 13) steroids were temporarily
administered during NK-DLI because of more adverse effects
(vomiting and blood pressure fluctuation). Patients of group II did
not develop GvHD.grade II in response to NK-DLIIL-2 stim,
independent of the amount of stimulated T cells. In group I,
one patient (No. 1) treated with NK-DLIunstim containing
.50.000610
3/kg BW CD3
+ cells and the patient with the highest
amount of residual T cells in the graft (No. 5) developed
GvHD.grade II. Following the full myeloablative conditioning
regime, patients were in aplasia until engraftment was seen in both
patients’ subgroups, excluding patient No. 2 and No. 16, on days
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neutrophils (.1000/ml), respectively.
Therefore, data of all day +3 NK-DLIunstim applications were
not evaluable, since to that early time point post SCT, patients
were still in aplasia (median cell counts in PB at day +3: leukocytes
120/ml, lymphocyte 0/ml, NK cells 0/ml, monocytes 0/ml).
Because infusion of NK-DLIunstim at day +3 did not lead to any
changes, analyses were not included in any of the following figures.
Specific immune reconstitution of CD56
+CD3
2 NK cells post
haplo-SCT was very similar in both groups (Fig. S2B). Chimerism
analyses of PB and bone marrow beginning between day +11 and
+15 showed complete donor chimerism in 14/16 patients to that
early time point post SCT. Complete chimerism retained in 14/16
patients at day +40 and in 14/15 at day +100 post haplo-SCT
(Table 1). Also subtype chimerism analyses of CD56
+ NK cells
were performed in 5/16 patients which reflected results of total PB
and BM chimerism (data not shown). The only patient that did not
reach complete chimerism at day +40 (No. 2) rejected the stem cell
graft and underwent a second SCT. Further, in patient No. 16 no
chimerism analyses could be performed because of failure of
immune reconstitution and early death at day +27.
Overall, 7/9 patients receiving NK-DLIIL-2 stim and 5/9
receiving NK-DLIunstim have not been in remission (NR) or in
partial remission (PR) at the time point of SCT, while all patients
in remission were $second complete remission (CR2). Further-
more, 44% of these high risk patients are alive with regard to both
NK-DLIIL-2 stim and NK-DLIunstim groups with a mean follow up
of 20 and 45 months, respectively. KIR mismatch was seen in 6/9
patients of group I and 8/9 in group II in GvL/T direction and in
6/9 in both groups in HvG direction (Table 2). Nevertheless, in
this heterogeneous patient cohort, no clear influence on survival,
GvHD and rejection with regard to KIR mismatch could be seen.
Of note, effects of NK-DLIIL-2 stim application on PB leukocytes
in patient No. 16 were not evaluable because of failure of immune
reconstitution (Table 1). Further, measurements of the 2
nd NK-
DLIIL-2 stim application of patient No. 14 (d +98, cryopreserved)
were excluded, since the DLI has been washed prior to
administration because the patient had shown severe reaction to
DMSO previously.
NK-DLIIL-2 stim but not NK-DLIunstim led to a significant
decrease of CD56
+CD3
2 NK cells in patient’s PB
Monitoring of the leucocyte subsets in patient’s PB before and
10 min, 1 h, 4 h and 24 h after NK-DLI was performed to receive
first insights of the host immune reaction on donor NK cell
immunotherapy (Fig. S1C). We focused our main interest on fresh
NK-DLI applications, because the cryopreservation process (cell
centrifugation, concentration in a smaller volume and dilution in
DMSO) results in cell count and cytokine/chemokine reduction
and could lead to an impairment of NK cell and cytokine
functionality.
All NK cell infusions were associated with a reduction in
circulating NK cells within 10 min of infusion, but this was
significantly greater in patients receiving NK-DLIIL-2 stim (Fig. 1A
fresh NK-DLIs). After a 5.5-fold decrease in absolute NK cell
counts 10 min post infusion of freshly applied NK-DLIIL-2 stim in
contrast to NK-DLIunstim (1.2-fold) (Fig. 1B, left), NK cell counts
recovered within 24 h to prior values. DLI volume did not
artificially lead to the reduced absolute NK cell count, since NK-
DLIIL-2 stim volumes made up around J of patient’s PB volume,
respectively (Fig. 1B, middle). In addition, in both subgroups the
ratio of the administered NK-DLI dose compared to the patient’s
NK cells in the PB newly reconstituted post haplo-SCT was
very similar (Fig. 1B, right). Importantly, the decrease in
CD56
+CD3
2NK cells was not due to a down-regulation or loss
of CD56 expression (Fig. S3B).
Effects of total NK-DLIIL-2 stim applications (fresh and
cryopreserved) were similar, thus NK cell disappearing was
delayed, compared to the fast diminishing after fresh infusions
(compare Fig. 1A and Fig. S4 total NK-DLIs).
Moreover, infusion of NK-DLIIL-2 stim led to a change in the
proportion of CD56
brightCD16
dim/2 and CD56
dimCD16
+ NK cell
subpopulations which was due to a more pronounced loss of
CD56
brightCD16
dim/2 NK cells (Fig. 1C fresh NK-DLIs). Similar
effects were seen after total NK-DLIIL-2 stim applications (Fig. S4
total NK-DLIs). Patients receiving NK-DLIunstim showed no
change in the proportion of NK cell subpopulations.
Of note, NK cells with the characteristics of the ex vivo IL-2
activated phenotype (CD56
brightCD16
+/2CD69
+NCR
highCD62L
2)
could not be detected in the PB at any time during in vivo monitoring,
thus not returning post 24 h (Fig. S3A+B). In addition, CD62L
+
expressing PB NK cells declined 10 min post NK-DLIIL-2 stim in the
same manner like total NK cells, also recovering within 24 h (Fig.
S3B+C). Therefore, reduction in total NK cell count post NK-
DLIIL-2 stim was due to both, a rapid decrease in transferred and
peripheral blood NK cells.
Loss of antigen presenting cells (APCs) in the PB after
infusion of NK-DLIIL-2 stim but not after NK-DLIunstim
Shortly after infusion of NK-DLIIL-2 stim there was a significant
loss of CD14
+ monocytes in the PB of all patients (median 15-fold
reduction). After disappearing almost completely, monocyte counts
recovered within 4 to 24 h to normal values like the ones prior to
infusion. This was the case following fresh NK-DLIIL-2 stim as shown
in Fig. 2A, as well as after all NK-DLIIL-2 stim applications in total
(Fig. S4 total NK-DLIs). In contrast, monocyte counts following
NK-DLIunstim remained unaffected. Furthermore, total CD45
+
CD14
2CD16
2HLA-DR
+CD85k
+CD33
+ myeloid dendritic cell
(mDC) and CD45
+CD14
2CD16
2HLA-DR
+CD85k
+CD123
+
plasmacytoid dendritic cell (pDC) count also significantly decreased
directly after NK-DLIIL-2 stim, recovering subsequently to normal
values within 24 h to 1 week (Fig. S4). Again, these effects could not
be observed after infusion of NK-DLIunstim. Measurements of DCs
were carried out in a single-platform approach verifying reliable
data even in low cell counts.
Distinct influence of NK-DLIIL-2 stim and NK-DLIunstim on
granulocytes, and T and B cells in the PB
Following all applications of NK-DLIIL-2 stim a significant loss of
eosinophil granulocytes (SSC
highCD45
brightCD16
2) combined
with a massive increase in absolute white blood cell (WBC) count
was observed (average 4-fold). This was caused by an intensive
gain of the main CD45
+ leukocyte proportion of neutrophil
granulocytes (SSC
highCD45
lowCD16
+) leading to its peak after 4 h
and then returning to normal values prior to infusion (Fig. 2B fresh
NK-DLIs). Similar effects were seen after total NK-DLIIL-2 stim
applications (Fig. S4 total NK-DLIs). In contrast, the distinctly
increased absolute WBC count in the PB of the monitored patients
could not be noted after NK-DLIunstim applications (data not
shown).
According to a delayed immune reconstitution of T and B cells
in the patients’ PB post haplo-SCT compared to an early NK cell
recovery, CD3
+ T cell and CD19
+ B cell counts at the time point
of NK-DLI at day +40 were relatively low (median 50/ml CD3
+,
and 58/ml CD19
+). NK-DLIIL-2stim led to a very slight decrease in
absolute T cell count within 4 h post NK-DLIIL-2 stim while B cell
count was not affected (data not shown).
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cytokine/chemokine concentration in patients’ PB was
demonstrated, thus varying from levels from the ex vivo
engineered DLI
Ex vivo IL-2 stimulation of highly purified donor NK cells led to
the secretion of high amounts of various chemokines e.g. IL-8,
MIP-1b, MCP-1, IP-10 and RANTES which play crucial roles in
leukocyte activation and chemo-attraction, as well as the
inflammatory cytokine IFN-c (Fig. 3A). In contrast, the median
concentration of the pro-inflammatory cytokine IL-6 was below
10 pg/ml. The indicated IL-2 concentration was due to the
supplementary addition of 1000 U/ml IL-2 during expansion
procedure. Since NK-DLIs have not been washed prior to infusion
according to the study protocol, to avoid loss of NK cells, the total
amount of the indicated cytokines/chemokines was applied during
fresh NK-DLIIL-2 stim.
In vivo analyses of cytokine/chemokine concentration in
patient’s PB post NK-DLIIL-2 stim revealed significant increases
in plasma levels up to 4 h following infusion. The pro-
Figure 1. NK-DLIIL-2 stim but not NK-DLIunstim led to a considerable disappearance of NK cells from PB. A) Absolute number of NK cells in
the PB of the patients was significantly reduced 10 min post NK-DLIIL-2 stim (grey) in contrast to NK-DLIunstim (white), which showed minimal influence
only. 24 h after NK-DLIIL-2 stim absolute number of NK cells recovered to the level before DLI. Only freshly applied NK-DLIs infused around day +40
post SCT are shown and were used for statistical calculations (n=7 NK-DLIIL-2 stim, n=6 NK-DLIunstim). Box and whiskers plots show minimum, lower
quartile, median, upper quartile and maximum of all measured data. For the 4 h level post NK-DLIunstim two values were available, only. p,0.05
indicated as *. B) Mean and SEM of all freshly applied NK-DLIIL-2 stim (grey) and NK-DLIunstim (white) applied around day +40 post SCT. Striped bars
indicate estimated patient’s PB volume and peripheral NK cell count at the time point of NK-DLI infusion. Left graph shows a mean 5.5-fold reduction
of absolute NK cell count in the PB as early as 10 min post NK-DLIIL-2 stim compared to a 1.2-fold decrease for NK-DLIunstim. Middle graph shows
relation of NK-DLI volume to total blood volume of patients (NK-DLIIL-2 stim volume: 825 ml6249, compared to PB volume: 3060 ml6789; NK-DLIunstim
volume: 128 ml619, compared to PB volume 3093 ml6749). DLI volume did not artificially lead to the reduced absolute NK cell count, since
NK-DLIIL-2 stim volumes made up maximally around J of patient’s PB volume. Right graph shows mean NK-DLI cell dose 610
6/kg BW (NK-DLIIL-2 stim
19.264.5; NK-DLIunstim 18.865.1) in relation to patient’s PB NK cells newly reconstituted post haplo-SCT around d +40 prior to NK-DLI (NK-DLIIL-2 stim
26.068.5; NK-DLIunstim 31.964.0). Applied NK dose compromised about 80% of PB NK cells, illustrating the high dose of administered NK-DLI. C)
Density plots (CD56 vs. CD16) and box and whiskers plots show a significant change in the distribution of the cytotoxic CD56
dimCD16
+ and immune
regulatory CD56
brightCD16
dim/2 NK cell subsets. This was due to an absolute reduction of the CD56
brightCD16
dim/2 NK cell subpopulation in the PB
10 min after freshly applied NK-DLIIL-2 stim applications infused around d +40 (left; n=7). This could not be shown after NK-DLIunstim (right; n=6). Plots
are gated on CD56
+CD3
2 NK cells. For the 4 h level post NK-DLIunstim 2 values were available, only. p,0.05 indicated as *.
doi:10.1371/journal.pone.0027351.g001
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IL-8, MCP-1 and MIP-1b plasma concentrations peaked within
10 min to 1 h post NK-DLIIL-2 stim while recovering to their base
level within the next 24 h (Fig. 3B fresh NK-DLIs). In addition,
high plasma levels of the chemokines IP-10 and RANTES, acting
on both leukocyte activation and attraction, were detected but not
varying (data not shown). Similar results post infusions of
cryopreserved NK-DLIIL-2 stim were obtained, but to a slighter
extent, which was probably due to a reduction in cytokine/
chemokine concentration during the cryopreservation process.
Nevertheless, analyses of all NK-DLIIL-2 stim in total showed
identical results and did not change the overall conclusion (Fig. S4
total NK-DLIs). In comparison, no increase in plasma concentra-
tion of the indicated cytokines/chemokines following NK-
DLIunstim was detected (Fig. 3B). Besides, TNF-a, TNF-b, GM-
CSF, MIP-1a, FasL, IL-13 were secreted during ex vivo IL-2 NK
cell expansion, but either they could not be detected in patient’s
PB, or NK-DLIIL-2 stim did not lead to any changes in present
plasma concentrations (data not shown). IL-1b, IL-4, IL-7, IL-10,
IL-12p70, IL12/23 and G-CSF were analyzed as well, but were
not detected in NK-DLI and PB.
When focusing on one hand on the ex vivo cytokine/chemokine
levels in the NK-DLIIL-2 stim products and on the other hand on
patients’ PB levels measured directly after infusion, marked
variations occurred. Being aware that besides other factors i.e.
dilution effects need to be considered, IL-2, IL-8, IFN-c and
especially MIP-1b were found in lower concentrations in the PB
than in the NK-DLIIL-2 stim (Fig. 3A+B).
Discussion
Here we present first interesting insights from our clinical NK
cell phase I/II study using allogeneic NK-DLIunstim compared to
NK-DLIIL-2 stim in pediatric patients suffering from high risk
malignancies. Although, we, among others, have shown that the
infusion of unstimulated as well as previously ex vivo IL-2
stimulated allogeneic NK cells post haplo-SCT is well tolerated
without inducing severe GvHD.grade II [2,12,14,16], possible
Figure 2. Influence of NK-DLIs on monocyte and granulocyte distribution in patient’s PB. A) Significant reduction of absolute CD14
+
monocyte count could be demonstrated in patient’s PB 10 min after application of fresh NK-DLIIL-2 stim (n=7), while recovering to normal values
within the next 24 h. This was not seen after NK-DLIunstim (n=6). Density plots show side scatter (SSC) vs. CD14 gated on CD45
+ leukocytes. For the
4 h level post NK-DLIunstim 2 values were available, only. p,0.05 indicated as *. B) We observed a distinct influence of NK-DLIIL-2 stim on neutrophil and
eosinophil granulocyte count. A massive increase of neutrophils (SSC
highCD45
lowCD16
+) with its peak at 4 h was combined with a significant
reduction of eosinophil granulocytes (SSC
highCD45
brightCD16
2) in the PB after fresh NK-DLIIL-2 stim (n=7). This was not observed after unstimulated NK
cell applications (data not shown). p,0.05 indicated as *.
doi:10.1371/journal.pone.0027351.g002
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27351risks or disadvantages need to be critically discussed. As it stands,
literature is scarce about the fate and behavior of adoptively
transferred allogeneic NK cells in humans and about the potential
distinct influences of unstimulated NK cells in contrast to
previously ex vivo activated NK cells on patient’s adaptive and
innate immune system.
Figure 3. In vivo monitoring of patient’s cytokine/chemokine plasma levels following NK-DLI. A) Box and whiskers plots show the
respective cytokine/chemokine concentration present in the NK-DLIIL-2 stim product (n=12) immediately prior to infusion. The nine to 14 days ex vivo
IL-2 stimulation of highly purified donor NK cells led to the secretion of high amounts of various chemokines i.e. IL-8 and MIP-1b, as well as the pro-
inflammatory cytokine IFN-c. Whereas, the median concentration of the pro-inflammatory cytokine IL-6 was ,10 pg/ml. The indicated IL-2
concentration was due to addition during expansion procedure (see Material and Methods). Y-axis shows cytokine/chemokine concentration, range
1–1.000.000 pg/ml. B) Cytokine analyses of cryopreserved plasma samples collected before (pre) and 10 min, 1 h, 4 h and 24 h after fresh
NK-DLIIL-2 stim (X, n=6). Significant increases of in vivo cytokine/chemokine concentration of IL-2, IL-6, IL-8, IFN-c, MCP-1 and MIP-1b in patient’s
plasma following NK-DLIIL-2 stim were observed. Levels peaked after 10 min to 1 h post infusion, remained enhanced over a period of 4 h and
returned to base level within the next 24 h. In contrast, no increase in cytokine/chemokine PB concentration following NK-DLIunstim was seen
(N, n=2). p,0.05 and ,0.01 indicated as * and **.
doi:10.1371/journal.pone.0027351.g003
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concerning the capability to traffic to specific tissues, the regulation
of homing, and the survival of adoptively transferred cells in vivo.
NK cell trafficking to spleen, lymph nodes, lung, liver, gastroin-
testinal tissue and tumor side with a survival up to four weeks
following transfer was observed by a bioluminescence-based
strategy, which correlated with an observed anti-tumor effect
[24–26]. However, to date only one small clinical trial in humans
was performed, where three adult patients with renal cell
carcinoma received stimulated allogeneic NK cells labeled with
the radioactive substance Indium-111 oxine [27]. After an initial
accumulation in the lungs, NK cells redistributed to liver, spleen
and bone marrow as well as in two of four metastases in lung and
liver. Unfortunately, it has been reported as well that Indium
labeling significantly affects the cellular integrity [28]. Even though
it is still of particular interest if adoptively transferred NK cells in
humans actually reach their side of action, clinical trials using NK
cell labeling with potentially harmful substances will not obtain
approval in the treatment of pediatric malignancies. Therefore,
approaches using more noninvasive strategies have to be
considered. Our investigation is based on a comprehensive in vivo
cytokine/chemokine monitoring and on flow cytometric analyses
of quantification, constitution and distribution of various PB
leukocyte subsets before and after NK-DLI application.
In our study we have reported markedly diverse effects between
NK-DLIunstim and NK-DLIIL-2 stim. Shortly after infusion of NK-
DLIIL-2 stim only, a rapid almost complete loss of cells dominantly
from the innate immune system from patient’s PB circulation
appeared which was accompanied by significant increases in
plasma concentration of various cytokines and chemokines.
Whereas neutrophil granulocytes markedly increased within 4 h
post NK-DLIIL-2 stim, monocytes, dendritic cells, eosinophils and
especially NK cells massively decreased as early as 10 min post
infusion, while recovering within the next 24 h.
Moreover, when analyzing NK cells more into detail, we were
able to clearly discriminate between adoptively transferred and
patients’ PB NK cells by a distinct CD69, NCR and CD62L
expression. We have shown previously that ex vivo IL-2 stimulation
leads to a predominantly CD56
brightCD16
+/2 phenotype with a
strongly enhanced expression of the activation marker CD69,
while CD62L becomes down-regulated. Further, surface receptors
involved in NK cell cytotoxicity become highly up-regulated.
While only one-third of unstimulated NK cells, a median of 95%
of IL-2 stimulated NK cells show expression of NCRs. In detail,
NKp44, NKp30, NKp46 and NKG2D expression significantly
increased 33-fold, 12-fold, 3-fold and 4-fold, respectively [16].
Furthermore, the IL-2 stimulation led to a consistent increase in
NK cell killing activity against a neuroblastoma cell line [16] and
the leukemic cell line K562 (Fig. S2A). In addition, Penack et al.
showed that the CD16
2 NK cell subset is responsible for anti-
tumor responses [29].
NK cells with the characteristics of the ex vivo IL-2 stimulated
phenotype (CD56
brightCD16
+/2CD69
+NCR
highCD62L
2) were
not detected in patients’ PB at any time point during in vivo
monitoring. Furthermore, we could clearly show that the
significant reduction of CD56
+CD3
2 NK cells from blood
circulation following NK-DLIIL-2 stim was due to both, a decrease
in patients’ own PB CD62L
+ NK cells as well as a rapid
diminishing of the transferred, stimulated NK cells from the NK-
DLI with the CD62L
2 phenotype.
In contrast, PB cell subpopulations remained constant after NK-
DLIunstim. This effect was not due to NK-DLI dose, a PB dilution
effect after infusion, application date or host’s NK cell immune
reconstitution. All these variables were very similar in both,
patients receiving NK-DLIunstim and those receiving NK-
DLIIL-2 stim. The only difference was the IL-2 for generation of
NK-DLIIL-2 stim and the high amount of cytokines and chemokines
such as IFN-c, IL-8, MCP-1, IP-10, RANTES, MIP-1b secreted
in the course of ex vivo expansion. Those factors were only
transfused to patients treated with NK-DLIIL-2 stim.
In accordance with our results, early studies have reported a
rapid diminishing of various types of PB lymphoid cells, especially
NK cells, 15 min after in vivo bolus single cytokine administration
of very high doses of recombinant IL-2 (up to 1610
6 U/kg BW).
Similar to our study, cells also recovered within the next 24 h.
Furthermore, IL-2 was rapidly cleared from the plasma with a
half-life of 6.9 min [30,31]. It has been suggested that the IL-2
induced disappearance of NK cells may be related to a massive
adhesion to the activated endothelium [31,32]. Our observed
effects cannot be attributed to one single cytokine/chemokine but
to the whole cytokine ‘‘cocktail’’ applied with the NK-DLIIL-2 stim
product, but the IL-2 dose applied by our NK-DLI study was
extremely lower (,2610
4 U/kg BW) in comparison to the
discussed data by Lotze et al. (,1610
6 U/kg BW). Apparently,
much lower concentrations of IL-2 but in combination with our
indicated cytokines/chemokines administered by NK-DLIIL-2 stim
led to a comparable effect to high dose single IL-2 application with
regard to PB leukocyte diminishing.
Measuring cytokine/chemokine production is an integral part of
measuring immune response during immunotherapy. Because
cytokines act in networks and have overlapping functions,
monitoring of a single cytokine may be of limited use [33].
Following NK-DLIIL-2 stim we have shown significant increases in
plasma concentration of several chemotactic and inflammatory
cytokines and chemokines which remained enhanced up to 4 h
post DLI (Fig. 3B). The majority of the analyzed increases were
probably induced by the infusion of high amounts of ex vivo
generated cytokines/chemokines in the NK-DLIIL-2 stim.W e
assume that these changes in the natural cytokine milieu of the PB
led to the observed cell migration processes. The massive increase
of blood neutrophils, which represent the major early cell type to
invade inflammatory foci, is likely mediated by the transfer of high
amounts of IL-8 that were produced in the course of ex vivo NK cell
stimulation. Notably, IL-8 has been described to be the major
chemo-attractant for neutrophil granulocytes. Neutrophils are
described to be potent producers of various cytokines (i.e. IL-6, IL-
8, IP-10, MIP-1a/b) which may be in relation to the prolonged
enhanced cytokine/chemokine levels 4 h post NK-DLIIL-2 stim
application [34,35].
Furthermore, the disappearance of various leukocyte subsets
occurring only after NK-DLIIL-2 stim may be mediated by two
alternative or complementary mechanisms: (i) adherence to the
activated endothelium induced by high amounts of co-infused
cytokines/chemokines, (ii) leukocyte migration from the PB into
the extravascular compartment.
Although normal endothelial cells exhibit low affinity for
circulating lymphocytes, the high amount of the cytokines and
chemokines present in the PB (i.e. IFN-c, MIP-1b, IL-8), similar to
those released in the course of inflammation and other immune
reactions, leads to endothelial activation associated with an
increased expression of surface antigens which interact with all
leukocytes [31]. This might result in endothelial adherence and
therefore diminishing of leukocytes from blood circulation.
Further, it is known that soluble cytokines and chemokines bind
endothelial molecules including glycosaminoglycans (GAGs) and
the Duffy antigen/receptor for chemokines (DARC), which are
involved in the trans-endothelial transport of several chemokines,
i.e. MIP-1b, IL-8, RANTES, MCP-1 and IP-10 [36–38].
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provide a trans-cellular chemotactic gradient guiding leukocyte
extravasation [39]. Therefore, we assume that following the firm
attachment to the activated endothelium, the cells migrate across
the endothelium barrier into the tissue, actually leaving PB blood
circulation. Although 7-AAD analyses revealed no increase in
dead cells over the whole period of in vivo monitoring (data not
shown), a cell reduction in PB circulation due to cell death cannot
be excluded completely.
In addition to the discussed trans-endothelial transport of
cytokines/chemokines, cytokine stability in circulation, renal
clearance as well as dilution effects during infusion must be
regarded as parameters that have likely contributed to the
described discrepancy between high ex vivo levels in the NK-DLI
and much lower in vivo PB levels. In our study we found a
significant reduction of the immune regulatory CD56
bright
CD16
dim/2 NK cell subpopulations 10 min after NK-
DLIIL-2 stim. An explanation for the overall higher susceptibility
of the CD56
brightCD16
dim/2 NK cell subpopulation might be the
high expression of various chemokine receptors i.e. the MIP-1b
corresponding CCR5 receptor on the cell surface of the
CD56
brightCD16
dim/2 subpopulation, only [40].
Finally, IL-6 was the only cytokine which was secreted much
higher in the PB of our patients compared to those during NK cell
expansion, leading us to suspect a secondary production of the
patient’s body in response to NK-DLIIL-2 stim. We speculate that
this could be due to both, the secretion of endothelial cells in
reaction to the changing cytokine milieu, neutrophil granulocytes
and monocytes that transiently adhere to the endothelial surface.
In addition, the increase of IL-6 in patients’ blood plasma as a
response to NK-DLIIL-2 stim correlated with our clinical observa-
tions of transient fever and chills; therefore serving as a surrogate
marker of the biological activity of the ex vivo secreted and co-
infused cytokines and chemokines.
Till now, very little is known about the effects of NK cell
administration post SCT. These concomitant results to a clinical
immunotherapy study provide first insights on the distinct
influence of unstimulated vs. ex vivo IL-2 stimulated NK cell
infusions. Nevertheless, we are fully aware that dissimilarities in
the study design and the heterogeneous small patient cohort may
have a potential effect on the results and that further studies have
to verify the discussed data.
Moreover, an open issue remains the clinical benefit of NK-
DLIIL-2 stim compared to NK-DLIunstim applications. Due to our
heterogeneous patient cohort regarding different high risk diseases,
with multiple and advanced relapses, mostly not in remission (NR),
a clear evidence cannot be made. Anyhow, in the present study we
could show a superior cytotoxicity of ex vivo IL-2 stimulated
compared to unstimulated NK cells against the MHC-I negative
cell line K562 and against a neuroblastoma (NB) cell line as well
[16]. Cautiously it has to be noted, that 78% of the high risk group
II patients treated with NK-DLIIL-2 stim has not been in remission
during haplo-SCT, but reached a survival of 44%. In addition in
this group, two out of four patients suffering from high risk NB
stadium IV with a very poor prognosis are still alive .2 years post
NK-DLIIL-2 stim, which seems promising and is in accordance with
the enhanced lytic activity of IL-2 stimulated NK cells compared
to NK-DLIunstim against NB [16].
Conclusively, we were able to show that the adoptive transfer of
NK-DLIIL-2 stim results in massive cell migrating processes under
the influence of various ex vivo and most likely also in vivo secreted
cytokines and chemokines. Since IL-2 activation leads to an
improved cytotoxic capacity of the adoptively transferred NK
cells, the co-transfused cytokine milieu may promote NK cell
trafficking as well as an enhanced efficacy of NK cell immuno-
therapy.
Supporting Information
Figure S1 Study designs of the clinical phase I/II NK-
DLI and our concomitant in vivo monitoring analyses. A)
In a phase I/II clinical feasibility study starting in the year 2003,
haploidentical donor NK cells were isolated from unstimulated
leukapheresis and purified by a two-step CD3-depletion/CD56-
selection procedure. For haplo-SCT (d 0), peripheral blood stem
cells (PBSC) were purified immunomagnetically either by CD34-
selection or CD3/CD19-depletion. For NK cell collection,
leukapheresis was performed at day 210 prior and +40 post
SCT. At day +40, NK-DLIunstim was applied freshly, directly at
the end of the purification process, while the processed NK-
DLIunstim from day 210 was split and cryopreserved for the NK
cell application on day +3 and +100. B) In an amendment of the
study starting in the year 2005 two leukapheresis products
collected on day +29 and +30 post SCT were pooled for the
CD3-depletion/CD56-selection NK cell purification process.
Following purification, NK cells were further ex vivo expanded
and activated using 1000 U/ml IL-2 for 10 (9 to 14) days obeying
GMP. After ex vivo stimulation, the NK cell product was split up,
while one half was infused freshly at day +40 and the other was
cryopreserved and applied at day +100 post SCT. For haplo-SCT
(d 0), peripheral blood stem cells (PBSC) were purified
immunomagnetically by CD3/CD19-depletion. C) For our
concomitant in vivo monitoring study during NK-DLI, PB samples
were collected at the day of application before (pre), 10 min, 1 h,
4 h and 24 h after the end of NK-DLI application.
(TIF)
Figure S2 A) NK cell cytotoxicity of NK-DLIunstim vs. NK-
DLIIL-2 stim. Cytotoxic activity of donor NK cells against K562
was significantly enhanced by IL-2 stimulation. The killing activity
against the MHC class I negative leukemic cell line K562 of IL-2
stimulated NK-DLIs (grey, n=9) was significantly greater
compared to unstimulated NK cells (white, n=9) at both
effector:target ratios 1:1 and 10:1. NK cell cytotoxicity of freshly
isolated unstimulated or IL-2 stimulated products was tested
previously to application to the patients and/or before cryopres-
ervation. Cytotoxicity was analyzed based on a 5-color flow
cytometric single platform assay [19] and defined as the loss of
viable target cells in relation to the mono-cultured control. p,0.01
and ,0.001 indicated as ** and ***. B) In vivo NK cell
immune reconstitution post haplo-SCT. Similar NK cell
immune reconstitution post haplo-SCT in both patients’ groups
receiving NK-DLIIL-2 stim and NK-DLIunstim respectively. Very
similar NK cell immune reconstitution was seen in both patient
subgroups NK-DLIunstim (%, n=7) and NK-DLIIL-2 stim (m,
n=6). Immune reconstitution of all patients was monitored
regularly; within the first three months post SCT weekly, from
month four to six twice a month, followed by a period of monthly
analyses. Shown are all measurements and median performed in
each interval which were similar in both groups.
(TIF)
Figure S3 In vivo NK cell phenotype in patients PB
differs from that of ex vivo expanded NK-DLIIL-2 stim.
A) Upon 9–14 days of IL-2 stimulation, CD56, NKp44 and the
activation marker CD69 become highly up-regulated, while the
expression of the lymph node homing molecule CD62L declines.
This figure exemplarily shows the ex vivo IL-2 stimulated NK cell
phenotype present in the fresh NK-DLIIL-2stim. Density plots show
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CD3
+ T cells and CD19
+ B cells), CD56 vs. NKp44, CD56 vs.
CD69 and CD56 vs. CD62L (CD56-PC7, gated on CD56
+CD3
2
NK cells). B) The NK cell phenotype of the NK-DLIIL-2 stim (Fig.
S3A) was not present at any time following NK-DLIIL-2 stim
application in patients’ PB. This was indicated by the red circles.
The blue squares highlight the CD62L expression of PB NK cells
of the patients, illustrating the loss of the CD62L
+ expressing PB
NK cell phenotype as early as 10 min post NK-DLIIL-2 stim
infusions, and the recovering after 24 h. In addition, CD56 was
not down-regulated after NK-DLIIL-2 stim application. Density
plots show CD56 vs. CD16 (CD56-PE, gated on lymphocytes
excluding CD3
+ T cells and CD19
+ B cells), CD56 vs. NKp44,
CD56 vs. CD69 and CD56 vs. CD62L (CD56-PC7, gated on
CD56
+CD3
2 NK cells). C) The decline in CD62L expressing PB
NK cells was further illustrated by a box and whiskers plot. In the
PB nearly all of the minor CD56
bright and about 40% of the major
CD56
dim NK cell subpopulation are CD62L
+. As early as 10 min
post NK-DLIIL-2 stim applications (n=4) a significant reduction in
CD62L
+ expressing PB CD56
+CD3
2 NK cells was seen, while
returning after 24 h. p,0.05 is indicated as *.
(TIF)
Figure S4 Impact of total NK-DLIIL-2 stim applications
on leukocyte subpopulations and cytokine/chemokine
levels. This figure gives an overview of all NK-DLIIL-2 stim
applications, fresh and cryopreserved, in total. All effects of freshly
applied NK-DLIIL-2 stim on leukocyte subpopulations shown in
Fig. 1, 2, 3 were comparable to those presented in the overall of all
NK-DLIIL-2 stim applications (n=13). Box and whiskers plots show
minimum, lower quartile, median, upper quartile and maximum
of all measured data. Cytokine analyses of PB plasma samples
collected before (pre) and 10 min, 1 h, 4 h and 24 h after fresh
and cryopreserved NK-DLIIL-2 stim in total. Similar significant
increases of in vivo cytokine/chemokine concentration of IL-2, IL-
6, IL-8, IFN-c, MCP-1 and MIP-1b in patient’s plasma compared
to exclusively fresh NK-DLIIL-2 stim applications (Fig. 3) were
observed. Y-axis shows cytokine/chemokine concentration, range
1–1.000.000 pg/ml. p,0.05, p,0.01 and p,0.001 are indicated
as *, ** and ***, respectively.
(TIF)
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